News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,876 Results
Type
Article (14203)
Company Profile (282)
Press Release (252391)
Section
Business (79532)
Career Advice (156)
Deals (13228)
Drug Delivery (35)
Drug Development (50449)
Employer Resources (31)
FDA (5719)
Job Trends (5128)
News (144427)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (911)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21651)
ALS (61)
Alzheimer's disease (836)
Antibody-drug conjugate (ADC) (88)
Approvals (5735)
Artificial intelligence (112)
Autoimmune disease (13)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (20)
Breast cancer (142)
Cancer (1318)
Cardiovascular disease (112)
Career advice (135)
Career pathing (2)
CAR-T (107)
Cell therapy (308)
Cervical cancer (8)
Clinical research (40923)
Collaboration (500)
Compensation (228)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1385)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1295)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (79)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (29690)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48197)
Executive appointments (410)
FDA (6350)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (473)
Gene editing (90)
Generative AI (9)
Gene therapy (235)
GLP-1 (358)
Government (1075)
Grass and pollen (2)
Guidances (18)
Healthcare (6592)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (81)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (18)
IPO (7263)
IRA (11)
Job creations (860)
Job search strategy (129)
Kidney cancer (6)
Labor market (4)
Layoffs (204)
Leadership (3)
Legal (1386)
Liver cancer (30)
Lung cancer (187)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (116)
MASH (49)
Medical device (2590)
Medtech (2591)
Mergers & acquisitions (6263)
Metabolic disorders (366)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (61)
Neuropsychiatric disorders (23)
Neuroscience (1215)
NextGen: Class of 2025 (2017)
Non-profit (854)
Northern California (1580)
Now hiring (21)
Obesity (186)
Opinion (100)
Ovarian cancer (60)
Pain (41)
Pancreatic cancer (51)
Parkinson's disease (111)
Partnered (8)
Patents (112)
Patient recruitment (68)
Peanut (35)
People (25529)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14446)
Phase II (19038)
Phase III (12043)
Pipeline (744)
Podcasts (47)
Policy (39)
Postmarket research (852)
Preclinical (6067)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (277)
Real estate (1422)
Recruiting (12)
Regulatory (8576)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (92)
Series B (60)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1395)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1973)
State (1)
Stomach cancer (4)
Supply chain (18)
Tariffs (3)
The Weekly (35)
United States (12290)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (37)
Last 7 days (403)
Last 30 days (1563)
Last 365 days (19929)
2025 (4962)
2024 (20565)
2023 (22414)
2022 (26827)
2021 (27810)
2020 (23360)
2019 (16230)
2018 (11746)
2017 (13750)
2016 (11846)
2015 (14356)
2014 (10395)
2013 (7486)
2012 (7533)
2011 (7622)
2010 (7434)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17234)
Australia (2921)
California (3577)
Canada (1061)
China (326)
Colorado (138)
Connecticut (143)
Delaware (88)
Europe (37074)
Florida (423)
Georgia (110)
Idaho (16)
Illinois (214)
India (9)
Indiana (87)
Iowa (1)
Japan (71)
Kansas (60)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (447)
Massachusetts (2820)
Michigan (69)
Minnesota (138)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (894)
New Mexico (12)
New York (969)
North Carolina (525)
North Dakota (4)
Northern California (1580)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (682)
Puerto Rico (3)
Rhode Island (15)
South America (209)
South Carolina (4)
Southern California (1395)
Tennessee (25)
Texas (412)
Utah (48)
Virginia (70)
Washington D.C. (28)
Washington State (325)
Wisconsin (13)
266,876 Results for "nbe therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
April 3, 2025
·
5 min read
Navigating CMC Challenges in NBE and Therapeutic Antibody Development
In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to reach. As of the fall of 2022, the FDA has approved 162 antibody
September 19, 2023
·
6 min read
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group
PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors.
December 10, 2020
·
3 min read
Business
Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube and pump formats.
May 24, 2022
·
2 min read
Deals
Bolstering Cancer Platform, Boehringer Acquires NBE for $1.4B USD
Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.
December 10, 2020
·
2 min read
·
Kate Goodwin
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Business
NBE-Therapeutics Appoints Dr. Steffen Heeger as Chief Medical Officer for Leading The Clinical Development of NBE’s iADC Programs
NBE-Therapeutics AG, a biopharmaceutical company developing best-in-class, immune-stimulatory antibody drug conjugates (iADCs™), announces the appointment of Dr. Steffen Heeger as Chief Medical Officer (CMO).
October 9, 2019
·
3 min read
Press Releases
CRISPR Therapeutics Announces Transition of Chief Operating Officer
March 26, 2025
·
1 min read
1 of 26,688
Next